肯尼亚退出Gavi支持后持续接种肺炎球菌疫苗的建模与成本效果研究
该建模与成本效果研究以肯尼亚为案例,拟合肺炎球菌携带动态区室模型,预测2022年后继续或停止接种肺炎球菌结合疫苗(PCV)的疾病负担与成本。结果显示停止接种将导致侵袭性肺炎球菌病(IPD)发病率上升,继续接种可避免死亡和病例,增量成本效果比为每避免一个伤残调整生命年(DALY)153美元(95% PI 70-411)。
要点
- 继续接种的增量成本效果比为每避免一个DALY 153美元(95% PI 70-411),基于肯尼亚人均GDP 1445美元具有成本效果。
核心结论
- 继续使用PCV对维持其健康收益至关重要。
- 基于肯尼亚人均GDP 1445美元,以全额成本继续接种PCV具有成本效果。
- 研究结果支持肯尼亚扩大疫苗预算。
研究设计与样本
- 建模与成本效果研究,以肯尼亚为案例。
- 拟合肺炎球菌携带的动态区室模型至基利菲的年度携带率调查和IPD发病率数据。
- 预测2022年后继续或停止PCV接种的疾病发病率和相关死亡率,计算每避免一个DALY的成本及95%预测区间(PI)。
主要发现
- 2022年后继续接种PCV相比停止接种每年需额外约1580万美元。
- 继续接种PCV的增量成本效果比在2032年为每避免一个DALY 153美元(95% PI 70-411)。
关键数值与推荐
- Gavi支持过渡阈值为三年人均国民总收入平均值1580美元。
- 肯尼亚人均GDP为1445美元。
- 继续接种PCV的增量成本效果比为每避免一个DALY 153美元(95% PI 70-411)。
临床怎么用
- 在规划退出Gavi支持时,应优先考虑以全额成本继续PCV接种以维持健康收益。
- 尽管可负担性可能令人担忧,但成本效果分析支持扩大疫苗预算。
- 决策时应参考当地人均GDP和增量成本效果比进行卫生经济学评估。
局限性
- 研究基于肯尼亚基利菲地区的模型预测,外推需谨慎。
- 成本效果分析基于疾病减少将转化为死亡率降低的假设。
- 可负担性可能仍是实际推广中的关注点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In 2009, Gavi, the World Bank, and donors launched the pneumococcal Advance Market Commitment, which helped countries access more affordable pneumococcal vaccines. As many low-income countries begin to reach the threshold at which countries transition from Gavi support to self-financing (3-year average gross national income per capita of US$1580), they will need to consider whether to continue pneumococcal conjugate vaccine (PCV) use at full cost or to discontinue PCV in their childhood immunisation programmes. Using Kenya as a case study, we assessed the incremental cost-effectiveness of continuing PCV use. METHODS: In this modelling and cost-effectiveness study, we fitted a dynamic compartmental model of pneumococcal carriage to annual carriage prevalence surveys and invasive pneumococcal disease (IPD) incidence in Kilifi, Kenya. We predicted disease incidence and related mortality for either continuing PCV use beyond 2022, the start of Kenya's transition from Gavi support, or its discontinuation. We calculated the costs per disability-adjusted life-year (DALY) averted and associated 95% prediction intervals (PI). FINDINGS: We predicted that if PCV use is discontinued in Kenya in 2022, overall IPD incidence will increase from 8·5 per 100 000 in 2022, to 16·2 per 100 000 per year in 2032. Continuing vaccination would prevent 14 329 (95% PI 6130-25 256) deaths and 101 513 (4386-196 674) disease cases during that time. Continuing PCV after 2022 will require an estimated additional US$15·8 million annually compared with discontinuing vaccination. We predicted that the incremental cost per DALY averted of continuing PCV would be $153 (95% PI 70-411) in 2032. INTERPRETATION: Continuing PCV use is essential to sustain its health gains. Based on the Kenyan GDP per capita of $1445, and in comparison to other vaccines, continued PCV use at full costs is cost-effective (on the basis of the assumption that any reduction in disease will translate to a reduction in mortality). Although affordability is likely to be a concern, our findings support an expansion of the vaccine budget in Kenya. FUNDING: Wellcome Trust and Gavi, the Vaccine Alliance.
引用
- Ojal J, Griffiths U, Hammitt LL, et al. Sustaining pneumococcal vaccination after transitioning from Gavi support: a modelling and cost-effectiveness study in Kenya. Lancet Glob Health. 2019. PMID: 31000132. doi:10.1016/S2214-109X(18)30562-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。